INTERFERON ENHANCED CC49 MONOCLONAL ANTIBODY IN METASTATIC PROSTATE CANCER

这项研究旨在确定一种抗体(CC49)是否已经被 用放射性核素131-I标记并注入静脉，将结合 主要是肿瘤，而不是正常组织，允许检测到 这些肿瘤通过扫描和治疗性放射治疗。这 放射性标记抗体131I-CC49是一种研究试剂。这个 与抗体结合的放射性活度大于 用于诊断性扫描，希望治疗剂量 辐射可以选择性地输送到肿瘤部位。131I- 抗体注射一次，作为一个疗程。干扰素， 一种刺激细胞表达的物质CC49 抗体与抗体反应，在抗体之前和之后给药。

This study is designed to determine if an antibody (CC49) which has been labeled with the radionuclide 131-I and injected into a vein, will bind primarily to tumors but not to normal tissues, allowing detection of these tumors by scanning and a therapeutic delivery of radiation. This radiolabeled antibody, 131I-CC49, is an investigational agent. The amount of radiatioactivity bound to the antibody is larger than that used for diagnostic scanning in hopes that therapeutic doses of radiation can be selectively delivered to the tumor sites. The 131I- antibody will be injected once, as a one treatment course. Interferon, an agent to stimulate cells to express the substance that the CC49 antibody reacts with, with be given before and after the antibody.